ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
MLN4924 suppresses kidney renal clear cell carcinoma progression through coordinated inhibition of Cullin1 neddylation and PSMB10-associated NF-κB inflammatory signaling.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundKidney renal clear cell carcinoma (KIRC) is characterized by malignant progression, inflammatory signaling, and therapeutic resistance. This study investigated whether MLN4924, a selective NEDD8-activating enzyme inhibitor, suppresses KIRC progression through coordinated regulation of Cullin1 neddylation, PSMB10 expression, and NF-κB signaling.
methodsKIRC cells were treated with MLN4924, followed by Western blotting, transcriptomic sequencing, pathway enrichment analysis, PSMB10 knockdown, and NF-κB pathway assessment. Complementary PSMB10 overexpression rescue experiments, together with colony formation and Transwell assays, were performed to test whether restoration of PSMB10 could reverse MLN4924-induced NF-κB inhibition and associated malignant phenotypes. A 786-O nude mouse xenograft model was used to evaluate the in vivo antitumor effects, tolerability, histological alterations, and molecular mechanisms of MLN4924.
resultsMLN4924 inhibited renal cancer cell growth and markedly reduced Cullin1-NEDD8 and PSMB10 protein levels. Transcriptomic analysis revealed extensive remodeling of lipid and sterol metabolism, extracellular matrix organization, cytokine and inflammatory signaling, growth factor-related pathways, and DNA replication-associated processes. MLN4924 treatment and PSMB10 knockdown both suppressed p65 phosphorylation, while combined intervention further inhibited phosphorylation of p65, IKKα/β, and IκBα. Conversely, PSMB10 overexpression partially restored p65 phosphorylation in MLN4924-treated ACHN and 786-O cells and significantly recovered colony formation, migration, and invasion. In vivo, MLN4924 significantly reduced tumor volume and weight, with an inhibition rate exceeding 30% and acceptable tolerability. Treated tumors showed increased apoptosis and necrosis, decreased Cullin-NEDD8, PSMB10, phospho-p65, TNF-α, IL-6, EMT/ECM remodeling markers, and proliferation-related proteins, and enhanced apoptotic signaling.
conclusionMLN4924 suppresses KIRC progression through inhibition of neddylation and attenuation of PSMB10-associated IKK/IκB/p65 NF-κB inflammatory signaling.
Indexed as
Identifiers
42802181What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.